Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Globus Medical (NYSE:GMED) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 1 | 2 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 1 | 0 | 0 | 0 |
3M Ago | 1 | 0 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $64.75, a high estimate of $71.00, and a low estimate of $58.00. Surpassing the previous average price target of $59.33, the current average has increased by 9.14%.
A clear picture of Globus Medical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Richard Newitter | Truist Securities | Raises | Hold | $60.00 | $58.00 |
Shagun Singh | RBC Capital | Maintains | Outperform | $70.00 | - |
Richard Newitter | Truist Securities | Raises | Hold | $58.00 | $53.00 |
Kyle Rose | Canaccord Genuity | Raises | Buy | $71.00 | $67.00 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Globus Medical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Globus Medical analyst ratings.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Globus Medical showcased positive performance, achieving a revenue growth rate of 50.95% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Globus Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.03%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Globus Medical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Globus Medical's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: GMED